# Is retatrutide safe? What the trials reported · PepVault

Source: https://pepvault.app/guides/is-retatrutide-safe

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Is retatrutide safe? What the trials reported

Reviewed November 2026 17 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 17
- **Questions:** 9
- **Compounds:** 2

## The short answer

Retatrutide is not approved anywhere yet. Its trial papers and Lilly describe its safety as consistent with the GLP-1 drug class: mostly stomach side effects, rare pancreatitis and gallbladder cases, no severe low blood sugar in the diabetes trials, deaths judged unrelated, and no clear heart-event difference from placebo in people with heart disease. Data run two years; the FDA calls off-trial products of unknown quality.

- Phase 2 registry results: 3 pancreatitis and 2 gallbladder cases among 457 people on retatrutide, none among 115 on placebo.
- TRIUMPH-3, adults with heart disease: 44 vs 52 major heart events on retatrutide vs placebo, no clear difference either way.
- No severe low blood sugar in the diabetes trials that report it; investigators judged the phase 3 deaths unrelated to the drug.
- Not approved anywhere as of November 2026; the FDA calls retatrutide sold 'for research purposes' of unknown quality.

Every number checked at its primary source · Nov 20, 2026 · [17 sources](https://pepvault.app/guides/is-retatrutide-safe#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomised phase 2 and phase 3 trials in people, all sponsored by Eli Lilly (NEJM, The Lancet, registry results); the phase 3 heart-event and several safety figures come from Lilly's company releases, and the off-trial evidence is two case reports.

## Is retatrutide safe in the trials so far?

So far, the trial reports say it behaves like the drug class it belongs to. Retatrutide switches on three hormone receptors at once: GLP-1, GIP and glucagon[1](https://pepvault.app/guides/is-retatrutide-safe#source-1). The two largest published phase 3 trials put their verdicts plainly. TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes for 80 weeks, found 'a safety profile generally consistent with other molecules with GLP-1 receptor agonism'[2](https://pepvault.app/guides/is-retatrutide-safe#source-2). TRANSCEND-T2D-1, 537 adults with type 2 diabetes for 40 weeks, found an adverse event profile consistent with the same class[3](https://pepvault.app/guides/is-retatrutide-safe#source-3). Lilly says the same of TRIUMPH-1, its 2,339-person obesity trial: the types of adverse events were generally consistent with other incretin-based drugs[8](https://pepvault.app/guides/is-retatrutide-safe#source-8).

That covers the side effects people feel most, the nausea, diarrhoea and skin tingling, which PepVault's guide to retatrutide side effects lays out trial by trial. This guide is about the rest of the safety question: the rare serious events, who the trials left out, and what the trials cannot show yet.

<!--promo-->

PepVault's side-effect log keeps each symptom with its date, the compound, a severity from minimal to very severe and a note, and the doctor's report puts them in one document beside your logged doses, so a clinician can see what happened and when. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-is-retatrutide-safe-inline&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's side-effect log keeps each symptom with its date, the compound, a severity from minimal to very severe and a note, and the doctor's report puts them in one document beside your logged doses, so a clinician can see what happened and when.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Did anyone get pancreatitis or gallbladder problems on retatrutide?

A handful of people. The two phase 2 trials, one in obesity and one in type 2 diabetes[4](https://pepvault.app/guides/is-retatrutide-safe#source-4) [5](https://pepvault.app/guides/is-retatrutide-safe#source-5), posted every serious adverse event to ClinicalTrials.gov, the federal trial registry. A serious adverse event is, for example, one that puts someone in hospital, threatens life or ends it, whatever the cause. Here is what they counted[6](https://pepvault.app/guides/is-retatrutide-safe#source-6) [7](https://pepvault.app/guides/is-retatrutide-safe#source-7):

| Serious event | Obesity trial: retatrutide (267) | Obesity trial: placebo (70) | Diabetes trial: retatrutide (190) | Diabetes trial: placebo (45) |
| --- | --- | --- | --- | --- |
| Acute pancreatitis | 1 | 0 | 2 | 0 |
| Gallbladder inflammation (cholecystitis) | 1 | 0 | 1 | 0 |
| Atrial fibrillation (irregular heartbeat) | 0 | 0 | 1 | 0 |
| Heart failure | 1 | 0 | 2 | 0 |
| Deaths | 1 | 0 | 0 | 0 |
| Anyone with a serious event | 10 (3.7%) | 3 (4.3%) | 11 (5.8%) | 3 (6.7%) |

The obesity trial counted events for up to 52 weeks and the diabetes trial for up to 280 days[6](https://pepvault.app/guides/is-retatrutide-safe#source-6) [7](https://pepvault.app/guides/is-retatrutide-safe#source-7). The diabetes trial's two pancreatitis cases came on the 0.5 mg dose and on 8 mg, not the top dose[7](https://pepvault.app/guides/is-retatrutide-safe#source-7). With groups this small, single cases can't give a rate. The phase 3 abstracts and Lilly's releases give no pancreatitis or gallbladder counts[1](https://pepvault.app/guides/is-retatrutide-safe#source-1) [2](https://pepvault.app/guides/is-retatrutide-safe#source-2) [3](https://pepvault.app/guides/is-retatrutide-safe#source-3) [8](https://pepvault.app/guides/is-retatrutide-safe#source-8) [9](https://pepvault.app/guides/is-retatrutide-safe#source-9), and no phase 3 trial has posted results to the registry yet, so those counts sit in the full papers' safety tables.

Both events are known for the approved drugs too. Zepbound's label lists acute gallbladder disease and acute pancreatitis among its warnings. In its weight-loss trials, gallbladder inflammation was reported in 0.7% on tirzepatide against 0.2% on placebo, and the label says acute gallbladder events were associated with weight reduction[14](https://pepvault.app/guides/is-retatrutide-safe#source-14). Retatrutide's phase 3 trials did not enrol anyone who had had pancreatitis[11](https://pepvault.app/guides/is-retatrutide-safe#source-11) [12](https://pepvault.app/guides/is-retatrutide-safe#source-12).

## Has anyone died taking retatrutide?

A few people died during the trials, and in the two phase 3 trials that report deaths, investigators judged none related to the drug. In TRIUMPH-2, two people died on 4 mg, three on 9 mg, one on 12 mg and one on placebo, and all deaths were deemed unrelated to the study drug by the investigator[2](https://pepvault.app/guides/is-retatrutide-safe#source-2). In TRANSCEND-T2D-1, two people died, both on 4 mg, both unrelated[3](https://pepvault.app/guides/is-retatrutide-safe#source-3). The phase 2 obesity trial recorded one death, a drowning[6](https://pepvault.app/guides/is-retatrutide-safe#source-6), and the phase 2 diabetes trial none[5](https://pepvault.app/guides/is-retatrutide-safe#source-5).

Large trials that run for a year or more expect some deaths from ordinary causes; that is why a placebo group is there. The count to watch is the gap between groups. In TRIUMPH-2, each retatrutide dose group had one to three deaths against one on placebo, numbers too small to show a pattern either way, and the investigators judged every one unrelated[2](https://pepvault.app/guides/is-retatrutide-safe#source-2).

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Incretin](https://pepvault.app/glossary/incretin)

## Does retatrutide cause heart problems?

Not so far, in the one finished trial of people with heart disease. TRIUMPH-3 randomised 1,949 adults (the registry lists 1,946) with severe obesity and established cardiovascular disease, meaning a past heart attack, stroke or narrowed leg arteries that cause symptoms, for 80 weeks; half got retatrutide 9 or 12 mg and half placebo[9](https://pepvault.app/guides/is-retatrutide-safe#source-9). Its main goal was weight loss, and Lilly also counted major adverse cardiovascular events (MACE), the heart-attack-and-stroke tally regulators use, in analyses planned in advance[9](https://pepvault.app/guides/is-retatrutide-safe#source-9):

| Heart events in TRIUMPH-3 | Retatrutide 9 and 12 mg | Placebo | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| MACE-5: death from any cause, heart attack, stroke, heart failure event or a procedure to reopen a heart artery | 44 | 52 | 0.82 (0.55 to 1.22) |
| MACE-3: heart death, heart attack or stroke | 27 | 23 | 1.12 (0.64 to 1.96) |

A hazard ratio below 1 means fewer events on the drug. Both ranges cross 1, so neither result shows a difference either way; events were also rarer than Lilly expected in both groups[9](https://pepvault.app/guides/is-retatrutide-safe#source-9). Along the way the top dose cut systolic blood pressure by 9.3 mmHg and triglycerides by 37.0%[9](https://pepvault.app/guides/is-retatrutide-safe#source-9). The resting heart rate rises in the first months and eases after; the side-effects guide gives that timeline.

The trial that settles it is TRIUMPH-Outcomes: about 10,000 adults aged 45 or older with obesity and artery or kidney disease, built to measure heart and kidney outcomes, expected to finish in February 2029[13](https://pepvault.app/guides/is-retatrutide-safe#source-13).

## Can retatrutide cause low blood sugar?

Not on its own, in the trials. The phase 2 diabetes trial reported no severe hypoglycaemia[5](https://pepvault.app/guides/is-retatrutide-safe#source-5), and neither did TRANSCEND-T2D-1, where retatrutide was the only diabetes drug[3](https://pepvault.app/guides/is-retatrutide-safe#source-3). In TRIUMPH-3, high blood sugar was the side effect that ran the other way: 3.9% and 3.1% on retatrutide against 13.4% on placebo[9](https://pepvault.app/guides/is-retatrutide-safe#source-9).

The risk changes with company. Zepbound's label warns that low blood sugar is more likely when it is used with insulin or a sulfonylurea, and says lowering the dose of those drugs may lower the risk[14](https://pepvault.app/guides/is-retatrutide-safe#source-14). That is a prescriber's adjustment to make, not a reason to stop either drug alone.

## Does the thyroid cancer warning apply to retatrutide?

Not formally, because retatrutide has no label yet; its trials treated the risk as if it did. Zepbound's label opens with a boxed warning, the FDA's strongest label warning: in rats, tirzepatide causes thyroid C-cell tumours, and it is unknown whether it does in humans[14](https://pepvault.app/guides/is-retatrutide-safe#source-14). The label rules it out for anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with multiple endocrine neoplasia type 2 (MEN 2), an inherited condition[14](https://pepvault.app/guides/is-retatrutide-safe#source-14).

Retatrutide's phase 3 trials excluded exactly those people[11](https://pepvault.app/guides/is-retatrutide-safe#source-11) [12](https://pepvault.app/guides/is-retatrutide-safe#source-12). Whether its future label carries the same box is the FDA's call at review. Until then, the rat finding is a warning the approved drugs in this class carry, and the label says its relevance to people has not been determined[14](https://pepvault.app/guides/is-retatrutide-safe#source-14).

## Who was left out of the retatrutide trials?

The trial numbers describe adults who passed these screens, so they say little about anyone outside them. From the registry records of TRIUMPH-1 and TRANSCEND-T2D-1[11](https://pepvault.app/guides/is-retatrutide-safe#source-11) [12](https://pepvault.app/guides/is-retatrutide-safe#source-12):

- Anyone under 18.
- Anyone who had had pancreatitis.
- Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
- People with type 1 diabetes.
- Anyone who had taken a weight-loss drug in the 90 days before screening, or had weight-loss surgery.
- In TRANSCEND-T2D-1 also: a heart attack, stroke or heart-failure hospital stay in the past 90 days, the most severe heart failure, active cancer or remission under five years, any past suicide attempt, severe low blood sugar in the past six months, very low kidney function and known stomach-emptying problems.

One of these groups, people with type 1 diabetes, has since turned up in a medical journal using retatrutide from outside the trials; the last section covers it.

## What is still unknown about retatrutide's safety?

- **Use past two years.** The longest data are TRIUMPH-1's extension to 104 weeks[8](https://pepvault.app/guides/is-retatrutide-safe#source-8). Obesity drugs are often taken for years.
- **Rare events.** The first TRIUMPH programme enrolled more than 5,800 people[9](https://pepvault.app/guides/is-retatrutide-safe#source-9). A side effect that hits 1 in 10,000 can hide in numbers like that; it surfaces after approval, when far more people take a drug.
- **Heart and kidney outcomes.** TRIUMPH-Outcomes reads out in 2029[13](https://pepvault.app/guides/is-retatrutide-safe#source-13).
- **The full safety tables.** TRIUMPH-3's heart-event figures come from Lilly's release so far, not a peer-reviewed paper[9](https://pepvault.app/guides/is-retatrutide-safe#source-9), and the phase 3 registry records carry no posted results yet[11](https://pepvault.app/guides/is-retatrutide-safe#source-11) [12](https://pepvault.app/guides/is-retatrutide-safe#source-12).
- **Approval.** As of November 2026 retatrutide is not approved by the FDA or any regulator anywhere, and Lilly plans to file with the FDA in the first quarter of 2027[9](https://pepvault.app/guides/is-retatrutide-safe#source-9) [10](https://pepvault.app/guides/is-retatrutide-safe#source-10).

## Is retatrutide sold online the same as the trial drug?

No, and every trial number above belongs to Lilly's drug alone. The FDA's statement, current as of October 1, 2026, is direct: retatrutide cannot be used in compounding under federal law, is not a component of any approved drug, and has not been found safe and effective for any condition[15](https://pepvault.app/guides/is-retatrutide-safe#source-15). The agency has warned telehealth companies for marketing it, ingredient distributors for selling it to compounders, and companies selling it labelled 'for research purposes' or 'not for human consumption', products it calls 'of unknown quality'[15](https://pepvault.app/guides/is-retatrutide-safe#source-15). Lilly states that anyone selling retatrutide to consumers is breaking the law[10](https://pepvault.app/guides/is-retatrutide-safe#source-10).

The journals now carry the first cases. A woman in her mid-20s had five days of nausea and vomiting after four weekly injections of an unverified product, given by a self-described life coach with no medical qualification; it resolved within a week[16](https://pepvault.app/guides/is-retatrutide-safe#source-16). A man with type 1 diabetes, one of the groups the trials excluded, was admitted with vomiting, rising ketones and later repeated low blood sugar after an online product, with a gut infection (Shigella) at the same time, so the case cannot say which caused what[17](https://pepvault.app/guides/is-retatrutide-safe#source-17). Single cases prove no rate; they show what the trial numbers don't cover. The legal side, by agency, is at pepvault.app/peptides/retatrutide/legal-status.

**When to get help** Belly pain that is severe and does not ease, sometimes spreading to the back, upper belly pain with a fever or yellowing skin or eyes, or vomiting that stops you keeping fluids down is a reason to get medical care the same day[14](https://pepvault.app/guides/is-retatrutide-safe#source-14).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
2. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. [PubMed 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/)
3. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. [PubMed 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/)
4. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. [PubMed 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/)
5. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. [PubMed 37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/)
6. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record: serious adverse events and deaths. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881760)
7. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Results record: serious adverse events and deaths. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867785)
8. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)
9. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html)
10. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)
11. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide (LY3437943) in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05929066)
12. ClinicalTrials.gov NCT06354660 (TRANSCEND-T2D-1). Effect of retatrutide compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06354660)
13. ClinicalTrials.gov NCT06383390 (TRIUMPH-Outcomes). The effect of retatrutide once weekly on cardiovascular outcomes and kidney outcomes in adults living with obesity (phase 3; sponsor Eli Lilly and Company). Record updated Oct 8, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383390)
14. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information: boxed warning and warnings and precautions. DailyMed, version 40, August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
15. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. [fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
16. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep. 2026. [PubMed 42843917](https://pubmed.ncbi.nlm.nih.gov/42843917/)
17. Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus. 2026. [PubMed 42669023](https://pubmed.ncbi.nlm.nih.gov/42669023/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)

Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)

  Retatrutide side effects by dose in its trials: nausea, diarrhoea, skin tingling and heart rate, when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)

  Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)

  Retatrutide's first dose in its trials: the 2 mg start, how long one shot lasts, when appetite and stomach effects showed up, and the first-shot routine.

  Read the guide
- Guide · GLP-1s

  ### [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)

  No trial has tested a switch from tirzepatide to retatrutide. What each drug's trials and the Zepbound label say, how the two differ, and what is still unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)

  Retatrutide not working? What the trials show: the climb to the top dose, how many people barely responded, why diabetes slows loss, and what a plateau is.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Incretin](https://pepvault.app/glossary/incretin)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
